Genesis Therapeutics Collaborates with NVIDIA and Secures Additional NVentures Funding to Accelerate AI-Driven Drug Discovery

Genesis Therapeutics has announced a collaboration with NVIDIA to advance its AI platform, GEMS (Genesis Exploration of Molecular Space). The partnership is bolstered by an additional equity investment from NVentures, NVIDIA’s venture capital arm, following its participation in Genesis’ $200 million Series B financing in August 2023.

See also: Unearthing New GEMS: Genesis and Gilead Collaborate to Tackle Tough Drug Targets

The collaboration will focus on optimizing advanced computational methods, particularly equivariant neural networks, to enhance the analysis of complex 3D molecular structures. These efforts aim to unlock new therapeutic possibilities for diseases with high unmet needs, including previously undruggable targets.

The GEMS platform integrates several innovative AI technologies:

• Language Models: Used to generate billions of drug-like molecules and predict ADME properties during lead optimization. These models allow chemists to target specific chemical spaces for improved results.
• Diffusion Models: To facilitate accurate predictions of protein-ligand structures, enabling efficient docking simulations and generation of highly accurate molecular poses.
• Physical Machine Learning: Combines molecular dynamics, quantum chemistry, and deep learning to optimize potency and selectivity, even for targets lacking substantial prior data.

GEMS functions as a molecular “search engine,” scanning chemical spaces to discover promising molecules.

Evan Feinberg, Ph.D., founder and CEO of Genesis Therapeutics:

“We look forward to combining our expertise and resources with NVIDIA’s to help realize our vision of harnessing AI to generate breakthrough therapies for diseases with high unmet need. Addressing previously undruggable targets to create new medicines requires pioneering algorithms for drug discovery and fundamental infrastructure innovation. Working with NVIDIA, we will further the capabilities of our field-leading physical AI platform for structure-driven drug design.”

Mohamed “Sid” Siddeek, corporate vice president at NVIDIA and head of NVentures:

“AI serves as a tool for discovering new therapies to treat diseases. Genesis’ AI platform, and related computational advancements developed in collaboration with NVIDIA, will help deliver novel generative and predictive AI techniques to explore untapped chemical pathways and identify drug candidates.”

Cover: sefa ozel

Topics: Startups & Deals